The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. BMJ 344:e3645

Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, 3755 Côte Sainte-Catherine, H-425.1, Montreal, Quebec, Canada H3T 1E2.
BMJ (online) (Impact Factor: 17.45). 05/2012; 344(may30 3):e3645. DOI: 10.1136/bmj.e3645
Source: PubMed


To determine if the use of pioglitazone is associated with an increased risk of incident bladder cancer in people with type 2 diabetes.
Retrospective cohort study using a nested case-control analysis.
Over 600 general practices in the United Kingdom contributing to the general practice research database.
The cohort consisted of people with type 2 diabetes who were newly treated with oral hypoglycaemic agents between 1 January 1988 and 31 December 2009. All incident cases of bladder cancer occurring during follow-up were identified and matched to up to 20 controls on year of birth, year of cohort entry, sex, and duration of follow-up. Exposure was defined as ever use of pioglitazone, along with measures of duration and cumulative dosage.
Risk of incident bladder cancer associated with use of pioglitazone.
The cohort included 115,727 new users of oral hypoglycaemic agents, with 470 patients diagnosed as having bladder cancer during follow-up (rate 89.4 per 100,000 person years). The 376 cases of bladder cancer that were diagnosed beyond one year of follow-up were matched to 6699 controls. Overall, ever use of pioglitazone was associated with an increased rate of bladder cancer (rate ratio 1.83, 95% confidence interval 1.10 to 3.05). The rate increased as a function of duration of use, with the highest rate observed in patients exposed for more than 24 months (1.99, 1.14 to 3.45) and in those with a cumulative dosage greater than 28,000 mg (2.54, 1.05 to 6.14).
The use of pioglitazone is associated with an increased risk of incident bladder cancer among people with type 2 diabetes.

Download full-text


Available from: Samy Suissa, Sep 29, 2015
1 Follower
79 Reads
  • Source
    • "and longer duration of administration (≥24 months, rate ratio 1.99, 95% CI 1.14–3.45) [1]. On the other hand, recently published results of propensity score matched cohort study did not find an association between pioglitazone and increased risk of bladder cancer in patients with type 2 diabetes (17,249 patients both in pioglitazone group and group exposed to other antidiabetic medications, HR 1.22, 95% CI 0.80–1.84) "
    [Show abstract] [Hide abstract]
    ABSTRACT: Diabetes increases cancer risk, which may be modulated by careful choice of treatment. Experimental reports showed efficacy of glitazones in various in vitro and in vivo models of carcinogenesis, but procarcinogenic effects in some models were reported too, and, similarly, data on cancer incidence in glitazone users are inconsistent. This review summarizes oncostatic effects of glitazones in preclinical and clinical studies and brings a brief summary of their impact on cancer risk in diabetic patients, with a focus on the association between pioglitazone use and bladder cancer.
    Pathology - Research and Practice 08/2014; 210(8). DOI:10.1016/j.prp.2014.06.003 · 1.40 Impact Factor
  • Source
    • "The breast cancer cohort was initially analysed using a nested case-control approach, a common approach [14,15] which accounts for immortal time bias [16] without requiring complicated statistical techniques [17] and with minimal loss of precision [18]. Time varying covariate cohort analyses were also applied and presented as described later. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Recent observational studies indicate that post-diagnostic use of aspirin in breast cancer patients may protect against cancer progression perhaps by inhibiting cyclooxygenase-2 dependent mechanisms. Evidence also supports a crucial role for interactions between tumour cells and circulating platelets in cancer growth and dissemination, therefore, use of low-dose aspirin may reduce the risk of death from cancer in breast cancer patients. A cohort of newly diagnosed breast cancer patients (1998-2006) were identified in the UK Clinical Practice Research Datalink (and confirmed by cancer registry linkage). Cancer-specific deaths were identified up to 2011 from Office for National Statistics mortality data. A nested case-control analysis was conducted using conditional logistic regression to compare post-diagnostic aspirin exposure using General Practice prescription data in 1,435 cases (breast cancer deaths) with 5,697 controls (matched by age and year of diagnosis). After breast cancer diagnosis, 18.3% of cancer-specific deaths and 18.5% of matched controls received at least one prescription for low-dose aspirin, corresponding to an odds ratio (OR) of 0.98 (95% CI 0.83, 1.15). Adjustment for potential confounders (including stage and grade) had little impact on this estimate. No dose response relationship was observed when the number of tablets was investigated and no associations were seen when analyses were stratified by receipt of prescriptions for aspirin in the pre-diagnostic period, by stage at diagnosis or by receipt of prescriptions for hormone therapy. Overall, in this large population-based cohort of breast cancer patients, there was little evidence of an association between receipt of post-diagnostic prescriptions for low-dose aspirin and breast cancer-specific death. However, information was not available on medication compliance or over-the-counter use of aspirin, which may have contributed to the null findings.
    Breast cancer research: BCR 04/2014; 16(2):R34. DOI:10.1186/bcr3638 · 5.49 Impact Factor
  • Source
    • "As suggested by two large observational studies, women taking TZDs have an increased risk of fractures as compared to those treated with other oral anti-diabetic drugs [147,148]. Similarly, TZDs have been associated with a questionable risk of bladder cancer [149-151]. Finally an increased prevalence of congestive hearth failure has been reported in patients on TZDs [152]. More debated remain the association between TZD use and cardiovascular events. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Type 2 diabetes mellitus (T2DM) is one of the most common chronic disorders in older adults and the number of elderly diabetic subjects is growing worldwide. Nonetheless, the diagnosis of T2DM in elderly population is often missed or delayed until an acute metabolic emergency occurs. Accumulating evidence suggests that both aging and environmental factors contribute to the high prevalence of diabetes in the elderly. Clinical management of T2DM in elderly subjects presents unique challenges because of the multifaceted geriatric scenario. Diabetes significantly lowers the chances of "successful" aging, notably it increases functional limitations and impairs quality of life. In this regard, older diabetic patients have a high burden of comorbidities, diabetes-related complications, physical disability, cognitive impairment and malnutrition, and they are more susceptible to the complications of dysglycemia and polypharmacy. Several national and international organizations have delivered guidelines to implement optimal therapy in older diabetic patients based on individualized treatment goals. This means appreciation of the heterogeneity of the disease as generated by life expectancy, functional reserve, social support, as well as personal preference. This paper will review current treatments for achieving glycemic targets in elderly diabetic patients, and discuss the potential role of emerging treatments in this patient population.
    Aging 03/2014; 6(3):187-206. · 6.43 Impact Factor
Show more